HonorHealth Research Institute commenced a clinical trial at three of its Arizona hospitals in Scottsdale and Phoenix to test a novel combination of atovaquone, a drug used to treat malaria and azithromycin, an antibiotic in a clinical trial to treat moderate to severe cases of SARS-COV-2, the virus behind the COVID-19 pandemic. This is the first such clinical trial in the United States involving this drug combination in connection to COVID-19 and Arizona leads the research charge.
The Problem: SARS-CoV-2
Michael Gordon, MD, a Co-principal investigator of the trial and Medical Director with HonorHealth Research Institute reports that doctors, scientists and researchers don’t yet understand this pathogen and cannot elucidate much of this disease. He noted, “A big challenge is about 80% of individuals develop flu-like symptoms for up to two weeks. Most of those go on to do well. But a subset, those at high risk who are over the age of 60, have diabetes, untreated hypertension and underlying illnesses that could suppress the immune system, about 15% of patients have a much more malignant progress.” For those that fall into the severe to critical category the virus can quickly g...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).